连接器
合理设计
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
蛋白质工程
化学
2019年冠状病毒病(COVID-19)
计算生物学
生物物理学
组合化学
纳米技术
生物化学
生物
计算机科学
酶
材料科学
传染病(医学专业)
医学
疾病
操作系统
病理
作者
Qin Qin,Xinyi Jiang,Liyun Huo,Jiaqiang Qian,Hongyuan Yu,Haixia Zhu,Wenhao Du,Yuhui Cao,Xing Zhang,Qiang Huang
标识
DOI:10.1186/s12951-024-02329-3
摘要
Multivalent drugs targeting homo-oligomeric viral surface proteins, such as the SARS-CoV-2 trimeric spike (S) protein, have the potential to elicit more potent and broad-spectrum therapeutic responses than monovalent drugs by synergistically engaging multiple binding sites on viral targets. However, rational design and engineering of nanoscale multivalent protein drugs are still lacking. Here, we developed a computational approach to engineer self-assembling trivalent microproteins that simultaneously bind to the three receptor binding domains (RBDs) of the S protein. This approach involves four steps: structure-guided linker design, molecular simulation evaluation of self-assembly, experimental validation of self-assembly state, and functional testing. Using this approach, we first designed trivalent constructs of the microprotein miniACE2 (MP) with different trimerization scaffolds and linkers, and found that one of the constructs (MP-5ff) showed high trimerization efficiency, good conformational homogeneity, and strong antiviral neutralizing activity. With its trimerization unit (5ff), we then engineered a trivalent nanobody (Tr67) that exhibited potent and broad neutralizing activity against the dominant Omicron variants, including XBB.1 and XBB.1.5. Cryo-EM complex structure confirmed that Tr67 stably binds to all three RBDs of the Omicron S protein in a synergistic form, locking them in the "3-RBD-up" conformation that could block human receptor (ACE2) binding and potentially facilitate immune clearance. Therefore, our approach provides an effective strategy for engineering potent protein drugs against SARS-CoV-2 and other deadly coronaviruses.
科研通智能强力驱动
Strongly Powered by AbleSci AI